{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotretinoin+%28Accutane%29", "query": { "intervention": "Isotretinoin (Accutane)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 99, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotretinoin+%28Accutane%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T21:05:48.257Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03076021", "title": "Effects of Isotretinoin on CYP2D6 Activity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "CYP2D6 Polymorphism" ], "interventions": [ { "name": "Isotretinoin", "type": "DRUG" }, { "name": "dextromethorphan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 33, "start_date": "2016-07-26", "completion_date": "2023-11-27", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03076021" }, { "nct_id": "NCT01183897", "title": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Months", "maximum_age": null, "sex": "ALL", "summary": "18 Months and older" }, "enrollment_count": 31, "start_date": "2010-08-12", "completion_date": "2018-09-25", "has_results": true, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183897" }, { "nct_id": "NCT00003619", "title": "Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Myelodysplastic Syndromes", "Thrombocytopenia" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "vitamin E", "type": "DIETARY_SUPPLEMENT" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "isotretinoin", "type": "DRUG" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "bone marrow ablation with stem cell support", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DIETARY_SUPPLEMENT", "DRUG", "PROCEDURE" ], "sponsor": "Drexel University College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "19 Years to 90 Years" }, "enrollment_count": null, "start_date": "1998-02", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003619" }, { "nct_id": "NCT03786783", "title": "Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ganglioneuroblastoma", "High Risk Neuroblastoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 42, "start_date": "2019-03-04", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 7, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03786783" }, { "nct_id": "NCT01711554", "title": "Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Neuroblastoma", "Refractory Neuroblastoma" ], "interventions": [ { "name": "Dinutuximab", "type": "BIOLOGICAL" }, { "name": "Isotretinoin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 27, "start_date": "2013-02-04", "completion_date": "2027-03-03", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 14, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711554" }, { "nct_id": "NCT03611595", "title": "Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "13-cis-retinoic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peter Zage", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "26 Years", "sex": "ALL", "summary": "2 Years to 26 Years" }, "enrollment_count": 15, "start_date": "2018-08-28", "completion_date": "2026-03-23", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 2, "location_summary": "San Diego, California • Atlanta, Georgia", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03611595" }, { "nct_id": "NCT01888289", "title": "Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fasting Condition", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Isotretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dr. Reddy's Laboratories Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "MALE", "summary": "18 Years to 45 Years · Male only" }, "enrollment_count": 35, "start_date": "2001-07", "completion_date": "2001-09", "has_results": false, "last_update_posted_date": "2013-06-27", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 1, "location_summary": "Quadrangle Drive, Chapel Hill,, North Carolina", "locations": [ { "city": "Quadrangle Drive, Chapel Hill,", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01888289" }, { "nct_id": "NCT00001504", "title": "A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Breast Neoplasm" ], "interventions": [ { "name": "9-cis-Retinoic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 18, "start_date": "1996-05", "completion_date": "2002-01", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001504" }, { "nct_id": "NCT00001073", "title": "Safety and Effectiveness of Giving Isotretinoin to HIV-Infected Women to Treat Cervical Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections", "Cervix, Dysplasia" ], "interventions": [ { "name": "Isotretinoin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "FEMALE", "summary": "13 Years and older · Female only" }, "enrollment_count": 150, "start_date": null, "completion_date": "2001-03", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001073" }, { "nct_id": "NCT01954641", "title": "Accountability for Cancer Care Through Undoing Racism and Equity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Lung Cancer" ], "interventions": [ { "name": "ACCURE Navigator", "type": "OTHER" }, { "name": "Usual Care by Cancer Center Care Team", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2013-04", "completion_date": "2018-03", "has_results": false, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-01T21:05:48.257Z", "location_count": 2, "location_summary": "Greensboro, North Carolina • Pittsburgh, Pennsylvania", "locations": [ { "city": "Greensboro", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01954641" } ] }